tiprankstipranks
Trending News
More News >
Lupin Limited (IN:LUPIN)
:LUPIN
India Market
Advertisement

Lupin Limited (LUPIN) AI Stock Analysis

Compare
7 Followers

Top Page

IN:LUPIN

Lupin Limited

(LUPIN)

Select Model
Select Model
Select Model
Outperform 72 (OpenAI - 4o)
Rating:72Outperform
Price Target:
₹2,172.00
▲(12.03% Upside)
Lupin Limited's overall stock score reflects its strong financial performance and fair valuation, tempered by mixed technical indicators. The company's robust revenue growth and profitability are significant positives, while the technical analysis suggests caution due to bearish momentum signals.

Lupin Limited (LUPIN) vs. iShares MSCI India ETF (INDA)

Lupin Limited Business Overview & Revenue Model

Company DescriptionLupin Limited is a global pharmaceutical company based in India, primarily engaged in the development, manufacturing, and marketing of a wide range of generic and branded medications. The company operates in various sectors, including pharmaceuticals, biotechnology, and specialty products, with a strong focus on therapeutic areas such as cardiovascular, diabetes, asthma, and infectious diseases. Lupin's core products include generic formulations, active pharmaceutical ingredients (APIs), and biosimilars that cater to both domestic and international markets.
How the Company Makes MoneyLupin Limited generates revenue through multiple key streams, including the sales of generic pharmaceuticals, branded formulations, and active pharmaceutical ingredients (APIs). A significant portion of the company's income comes from its generic drug portfolio, which includes a variety of medications that are sold at lower prices than their branded counterparts. Additionally, Lupin has a growing presence in the biosimilars market, which contributes to its revenue. The company also engages in strategic partnerships and collaborations with other pharmaceutical firms and research organizations, enhancing its R&D capabilities and expanding its product offerings. Furthermore, international markets, particularly in the United States and Europe, play a crucial role in Lupin's revenue generation, as the company focuses on obtaining approvals for new products and increasing its market share in these regions.

Lupin Limited Financial Statement Overview

Summary
Lupin Limited shows strong financial performance with robust revenue growth, profitability, and a stable balance sheet. The company has efficient cost management and operational efficiency, though cash flow conversion presents some challenges.
Income Statement
85
Very Positive
Lupin Limited has demonstrated strong revenue growth over recent years, with significant improvements in both gross and net profit margins. The gross profit margin for 2025 was 48.9%, indicating efficient cost management, while the net profit margin stood at 14.8%, reflecting strong profitability. Moreover, the company achieved a robust revenue growth rate of 12.9% from 2024 to 2025. The EBIT and EBITDA margins were also healthy at 20.1% and 24.7%, respectively, showcasing operational efficiency. The positive trajectory in these metrics highlights strong financial performance.
Balance Sheet
78
Positive
The balance sheet of Lupin Limited shows a solid equity base with a debt-to-equity ratio of 0.32, indicating moderate leverage. The return on equity (ROE) is impressive at 19.1%, showcasing efficient utilization of equity to generate profits. The equity ratio is healthy at 58.9%, pointing to a strong equity position relative to total assets. While the overall stability is good, potential risks could arise if debt levels increase significantly.
Cash Flow
72
Positive
Lupin Limited's cash flow statement reflects a positive free cash flow growth rate of -51.6% from 2024 to 2025, highlighting some challenges in cash generation. However, the operating cash flow to net income ratio of 0.91 suggests that the company is generating sufficient cash from operations relative to its earnings. The free cash flow to net income ratio stands at 0.40, indicating room for improvement in converting profits into free cash flow. While cash flow management appears stable, enhanced cash conversion could further strengthen financial positioning.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue233.76B227.08B200.11B166.42B164.05B151.63B
Gross Profit159.68B153.27B128.99B94.10B95.05B94.18B
EBITDA53.87B50.51B36.27B15.73B19.66B25.24B
Net Income36.99B32.82B19.14B4.30B-15.28B12.17B
Balance Sheet
Total Assets0.00292.05B239.97B229.56B218.21B236.10B
Cash, Cash Equivalents and Short-Term Investments29.90B42.01B21.79B19.52B21.04B41.11B
Total Debt0.0054.48B29.22B45.42B41.58B51.29B
Total Liabilities-172.94B119.11B96.24B104.13B95.99B97.52B
Stockholders Equity172.94B172.03B142.90B124.64B121.53B138.03B
Cash Flow
Free Cash Flow0.0013.18B27.19B3.98B-5.38B11.44B
Operating Cash Flow0.0030.00B36.48B18.97B3.67B18.22B
Investing Cash Flow0.00-41.72B-17.12B-12.87B12.92B-12.40B
Financing Cash Flow0.0017.32B-21.84B-3.37B-15.72B-18.85B

Lupin Limited Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price1938.85
Price Trends
50DMA
1958.15
Negative
100DMA
1947.16
Negative
200DMA
1984.89
Negative
Market Momentum
MACD
-6.55
Negative
RSI
49.23
Neutral
STOCH
62.91
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LUPIN, the sentiment is Neutral. The current price of 1938.85 is below the 20-day moving average (MA) of 1944.11, below the 50-day MA of 1958.15, and below the 200-day MA of 1984.89, indicating a neutral trend. The MACD of -6.55 indicates Negative momentum. The RSI at 49.23 is Neutral, neither overbought nor oversold. The STOCH value of 62.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:LUPIN.

Lupin Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
₹1.05T18.440.64%14.10%9.72%
₹1.27T23.630.83%6.40%25.27%
₹893.78B23.700.61%12.40%63.16%
₹993.45B21.731.10%14.52%9.46%
₹1.22T60.490.89%7.63%15.39%
₹1.02T53.210.04%21.66%-4.92%
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:LUPIN
Lupin Limited
1,956.80
-215.95
-9.94%
IN:CIPLA
Cipla Ltd
1,580.75
43.98
2.86%
IN:DRREDDY
Dr. Reddy's Laboratories Ltd.
1,252.60
-13.62
-1.08%
IN:MANKIND
Mankind Pharma Ltd.
2,445.75
-219.80
-8.25%
IN:TORNTPHARM
Torrent Pharmaceuticals Ltd
3,600.90
429.57
13.55%
IN:ZYDUSLIFE
Zydus Lifesciences Limited
986.30
-4.20
-0.42%

Lupin Limited Corporate Events

Lupin Limited’s PEGASUS Study: A New Horizon in Pediatric Myotonic Disorder Treatment
Oct 27, 2025

Study Overview: Lupin Limited is conducting a study titled ‘Prospective, Long Term, Observational Study (Patient Registry) of Paediatric Myotonic Disorders From Birth to Less Than Six Years of Age Who Are Treated With Mexiletine (PEGASUS Study).’ The study aims to gather clinical and epidemiological data from pediatric patients with myotonic disorders treated with mexiletine, highlighting its significance in understanding treatment outcomes in young children.

Lupin Limited’s ACHILLES Study: A New Horizon in Myotonia Treatment
Oct 27, 2025

Study Overview: Lupin Limited is conducting a study titled ‘An Open-Label, Randomized, Cross-Over Study to Investigate the Efficacy and Safety of Mexiletine PR Compared to Mexiletine IR in Patients With Non-Dystrophic Myotonias (ACHILLES Study)’. The study aims to evaluate the efficacy and safety of two formulations of mexiletine, a drug used to treat myotonia, a muscle disorder. This study is significant as it could lead to improved treatments for patients with non-dystrophic myotonias.

Lupin Limited’s Phase 3 Study on Mexiletine PR: A Potential Game-Changer for Myotonic Dystrophy
Oct 27, 2025

Lupin Limited is conducting a clinical study titled ‘A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Once Daily Mexiletine PR During 26 Weeks of Treatment in Patients With Myotonic Dystrophy Type 1 and Type 2.’ This Phase 3 study aims to evaluate the safety and efficacy of Mexiletine PR in treating Myotonic Dystrophy, a significant step in addressing this rare neuromuscular disorder.

Lupin Limited’s New Study on Mexiletine PR: A Potential Game-Changer for Myotonic Dystrophy Treatment
Oct 27, 2025

Study Overview: Lupin Limited is conducting an open-label extension study titled ‘An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed the MEX-DM-302 Study (ATLAS Study).’ The study aims to assess the long-term safety and efficacy of mexiletine PR in patients with myotonic dystrophy types 1 and 2, following their participation in the MEX-DM-302 study. This research is significant as it seeks to provide a prolonged treatment option for managing myotonia symptoms in these patients.

Lupin Limited Launches Generic Version of Ravicti® in U.S.
Oct 24, 2025

Lupin Limited has launched an authorized generic version of Ravicti® (Glycerol Phenylbutyrate) Oral Liquid, 1.1g/mL, in the United States, aimed at managing urea cycle disorders (UCDs) in patients who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. This strategic move is expected to enhance Lupin’s presence in the U.S. pharmaceutical market, potentially increasing its market share and providing a cost-effective treatment option for patients with UCDs.

Lupin Limited’s New Jersey Facility Undergoes FDA Inspection
Oct 11, 2025

Lupin Limited announced that the U.S. FDA conducted a Pre-Approval Inspection at its Somerset, New Jersey manufacturing facility, which concluded with one observation. The company is committed to addressing the observation promptly to ensure compliance with CGMP standards, reflecting its dedication to maintaining high-quality manufacturing practices.

Lupin’s Pithampur Facility Receives OAI Classification from U.S. FDA
Oct 4, 2025

Lupin Limited announced that the U.S. FDA has classified its Pithampur Unit-2 manufacturing facility inspection as ‘Official Action Indicated’ (OAI) following an earlier inspection that resulted in a Form-483 with four observations. The company is actively working with the FDA to address the compliance issues and ensure adherence to CGMP standards across all its facilities. This development may have implications for Lupin’s operations and its standing in the pharmaceutical industry, particularly in the U.S. market.

Lupin Limited Expands European Presence with VISUfarma Acquisition
Sep 29, 2025

Lupin Limited’s subsidiary, Nanomi B.V., has entered into a definitive agreement to acquire VISUfarma B.V., a specialty pharmaceutical company based in Amsterdam, Netherlands. VISUfarma focuses on ophthalmology and has a significant commercial presence across major European countries, offering products for dry eye, glaucoma, and other eye-related conditions. This acquisition is expected to enhance Lupin’s market positioning in the European ophthalmology sector, potentially expanding its product offerings and market reach.

Lupin Limited Announces Key Resolutions Passed via Postal Ballot
Sep 25, 2025

Lupin Limited has announced the successful passing of resolutions via a postal ballot, including the re-appointment of Mr. Mark D. McDade as an Independent Director and a revision in the remuneration of Managing Director Mr. Nilesh D. Gupta. These resolutions, passed with the requisite majority, reflect the company’s ongoing governance and operational adjustments, potentially impacting its strategic direction and stakeholder relations.

Lupin Limited Gains U.S. FDA Approval for Lenalidomide Capsules
Sep 17, 2025

Lupin Limited has announced that it has received approval from the U.S. FDA for its Abbreviated New Drug Application for Lenalidomide Capsules, which are bioequivalent to Revlimid® Capsules by Bristol-Myers Squibb. These capsules, intended for treating multiple myeloma and transfusion-dependent anemia, will be manufactured at Lupin’s Pithampur facility in India. The approval marks a significant milestone for Lupin, potentially enhancing its market presence in the U.S. pharmaceutical sector, given the high annual sales of Lenalidomide Capsules in the U.S. market.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 30, 2025